Improdia is Monitoring the Immune Status

Improdia is an innovative, diagnostic company that develops clusters of novel proprietary
biomarkers for monitoring the Immune Status of patients suffering from diseases associated with
Chronic Inflammation.
Improdia was established based on a project conceived in the Department of Immunology under

Proof of Concept
Biomarkers
The Test Kit
The Need
Current Situation

Roy Farfara Dr. MD.

MD Director

Roy Farfara Dr. MD.

MD Director

Dr. Farfara received his MD degree in Medicine from the Technion, has practiced as a physician and an urologist surgeon for 15 years, whilst also researching renal cancer, urinary exosomes and has acting as a principial/co-investigator in clinical and medical device trials. Roy has 10 years of experience in the pharmaceutical industry, as the founder of various biotech companies, some being in advanced clinical phases. Roy has led projects from inception, patenting and funding, to preclinical and clinical trials.

Miriam Lerner M.Sc.

CTO

Miriam Lerner M.Sc.

CTO

Ms. Lerner received her MSc in applied microbiology from the Hebrew University of Jerusalem. For over 18 years she has been involved in the R&D of diagnostic technologies, previously holding senior management positions in ImmunArray Ltd. and Procognia Ltd from their establishment stage. Miriam is experienced in leading project and research teams, as well as in managing QMS. Miriam has co-authored several scientific publications relating to her research.

Raphael Nir Ph.D.

Co-Founder

Raphael Nir Ph.D.

Co-Founder

Dr. Nir is a scientist, entrepreneur and angel investor with over 26 years of experience commercializing recombinant cytokines and pre-clinical contract research services. He is the co-founder of two pre-clinical contract research organizations: SBH Sciences and Woodland Biosciences; and three biotechnology companies: Karyopharm Therapeutics (NASDAQ: KPTI), Galectin Sciences and Alma Bio Therapeutics.

Michal Baniyash Prof.

Ph.D., Scientist

Michal Baniyash Prof.

Ph.D., Scientist

Prof. Baniyash received her Ph.D. in Immunology from the Weizmann Institute of Science, and now has more than 20 years of experience in conducting pioneering research, presently at the Hebrew University of Jerusalem. She has over 50 prestigious publications and numerous inventions on the field of biomarkers.

Gil Pogozelich Ph.D.

CHAIRMAN

Gil Pogozelich Ph.D.

CHAIRMAN

Dr. Pogozelich is highly experienced, for 20 years has been leading successful technology startups. Now specializes in the development, integration and commercialization of Life Science technologies, with emphasis on the field of personalized medicine. Previously specialized in the management of complex development teams in algorithms and engineering, and registered and co-registered a number of patents.